Triple threat: could adding radiation to immunotherapy and chemotherapy help fight advanced lung cancer?

NCT ID NCT05068232

Recruiting now Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is for people newly diagnosed with extensive-stage small cell lung cancer that has spread. Researchers want to see if adding a precise, high-dose radiation treatment (ablative radiation) to the standard combination of durvalumab (an immunotherapy) and chemotherapy (carboplatin and etoposide) can help control the cancer longer. About 49 participants will receive this triple therapy, and the study will track how long they live without the cancer progressing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab (immunotherapy), etoposide and carboplatin (chemotherapy), and ablative radiation therapy
What this could lead to: If successful, this combination could help people with extensive-stage small cell lung cancer live longer without their cancer getting worse.
What could go wrong: This is a small, early-phase trial (49 people) with no control group, so results may not be definitive. Adding radiation to immunotherapy and chemotherapy may increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER LUNG CANCER SMALL CELL LUNG CANCER

Contacts and locations

Locations

University of Chicago Medicine
RECRUITING

Chicago, Illinois, 60637, United States
University of Wisconsin Carbone Cancer Center
ACTIVE_NOT_RECRUITING

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.